Development and Validation of a Claims-Based Algorithm for Identifying Incident Colorectal Cancer and Determining Progression Phases.
1/5 보강
[PURPOSE] Health insurance claims comprising diagnosis and treatment information offer insights into clinical practice and medical care costs.
- 95% CI 89.5 to 92.7
APA
Agatsuma N, Utsumi T, et al. (2025). Development and Validation of a Claims-Based Algorithm for Identifying Incident Colorectal Cancer and Determining Progression Phases.. JCO clinical cancer informatics, 9, e2500107. https://doi.org/10.1200/CCI-25-00107
MLA
Agatsuma N, et al.. "Development and Validation of a Claims-Based Algorithm for Identifying Incident Colorectal Cancer and Determining Progression Phases.." JCO clinical cancer informatics, vol. 9, 2025, pp. e2500107.
PMID
41129774 ↗
Abstract 한글 요약
[PURPOSE] Health insurance claims comprising diagnosis and treatment information offer insights into clinical practice and medical care costs. However, inaccurate diagnosis codes listed in claims and the absence of staging information limit the understanding of colorectal cancer (CRC)-related clinical practice. We developed and validated an algorithm to accurately identify incident CRC cases and their progression phases using claims data.
[METHODS] We conducted a retrospective study using claims data from three Japanese institutions, including two designated cancer care hospitals (DCCHs), between April 2016 and August 2022. An algorithm that uses CRC-associated diagnostic codes and claim codes for CRC-specific treatments was developed to identify incident CRC cases and classify patients into three progression phases (treatment-sequenced groups: endoscopic, surgical, and noncurative). The algorithm was refined using cohorts from two DCCHs in April-September 2017 and April-September 2019 to enhance performance metrics, with validity tested at these hospitals during different periods and at another hospital. The performance metrics of the algorithm included positive predictive value (PPV), sensitivity in identifying incident CRC, and accuracy in determining progression phases.
[RESULTS] The performance metrics of the algorithm were enhanced by filtering prevalent cases, selecting CRC-specific treatments, and targeting invasive CRC cases. The algorithm for identifying incident invasive CRC achieved high PPVs (91.2% [95% CI, 89.5 to 92.7] and 94.4% [95% CI, 87.6 to 97.6]), sensitivities (94.6% [95% CI, 93.1 to 95.7] and 100.0% [95% CI, 95.7 to 100.0]), and progression phase accuracies (91.5% [95% CI, 89.7 to 93.0] and 97.6% [95% CI, 91.8 to 99.4]) in two validation cohorts.
[CONCLUSION] The developed algorithm accurately identified incident invasive CRC cases and determined their progression phases using claims data. Application of this algorithm could contribute to research on real-world practices and medical care costs associated with CRC.
[METHODS] We conducted a retrospective study using claims data from three Japanese institutions, including two designated cancer care hospitals (DCCHs), between April 2016 and August 2022. An algorithm that uses CRC-associated diagnostic codes and claim codes for CRC-specific treatments was developed to identify incident CRC cases and classify patients into three progression phases (treatment-sequenced groups: endoscopic, surgical, and noncurative). The algorithm was refined using cohorts from two DCCHs in April-September 2017 and April-September 2019 to enhance performance metrics, with validity tested at these hospitals during different periods and at another hospital. The performance metrics of the algorithm included positive predictive value (PPV), sensitivity in identifying incident CRC, and accuracy in determining progression phases.
[RESULTS] The performance metrics of the algorithm were enhanced by filtering prevalent cases, selecting CRC-specific treatments, and targeting invasive CRC cases. The algorithm for identifying incident invasive CRC achieved high PPVs (91.2% [95% CI, 89.5 to 92.7] and 94.4% [95% CI, 87.6 to 97.6]), sensitivities (94.6% [95% CI, 93.1 to 95.7] and 100.0% [95% CI, 95.7 to 100.0]), and progression phase accuracies (91.5% [95% CI, 89.7 to 93.0] and 97.6% [95% CI, 91.8 to 99.4]) in two validation cohorts.
[CONCLUSION] The developed algorithm accurately identified incident invasive CRC cases and determined their progression phases using claims data. Application of this algorithm could contribute to research on real-world practices and medical care costs associated with CRC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.